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Abstract
The incidence of one or other rearrangement in chronic myeloid leukemia (CML) patients varies in different reported
series. In this study we report the frequencies of BCR-ABL1 fusion transcript variants studied in 43 CML patients
from Sudan. The study includes 46 Sudanese patients, three of which negative for the BCR-ABL1 fusion transcript.
More than half of 43 positive patients showed b2a2 fusion transcript (53.5%), while (41.9%) showed b3a2 transcript
and the remaining (4.6%) coexpression of b3a2/ b2a2 and b3a2/b2a2/e19a2. We detected neither coexpression of
p210/p190 nor e1a2 alone. Male patients showed a tendency to express b2a2, while female tende to express b3a2
(p = 0.017). Moreover, a single nucleotide polymorphism was detected in BCR exon 13 in one out of four patients and
this patient showed only b2a2 expression. In conclusion, we observed a significant correlation between sex and type
of BCR-ABL1 transcript, an observation that deserves further investigation.
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The Philadelphia (Ph) chromosome was the first
chromosomal abnormality to be associated with a specific
malignant disease in humans, namely chronic myeloid leu-
kemia(CML).Thisisashortenedchromosome22resulting
from reciprocal translocation, t(9;22)(q34;q11), between
the long arms of chromosomes 9 and 22. This translocation
results in the formation of two hybrid genes, BCR-ABL1
on the Ph chromosome and ABL1-BCR on 9q+ (Melo,
1996). A Ph chromosome is the hallmark of CML and is
found in up to 95% of the patients. It is also found in 5% of
children and in 15 to 30% of adults with acute lymphoid
leukemia,andin2%ofpatientswithnewlydiagnosedacute
myeloblastic leukemia (Kurzrock et al., 1988).
In most CML patients, the break in chromosome 22 is
restricted to an area of 5.8-kb termed M-bcr. M-bcr consists
offiveexonstermedM-bcrexonsb1-b5.Theseexonsareac-
tually located within the central region of the BCR gene and
are equivalent to exons 12-16 (e12- e16) of this gene. Most
breaks occur immediately downstream of exon 2 or 3 of the
M-bcr region and result in b2a2 or b3a2 fusion transcripts
(Groffen et al., 1984). A very small proportion of Ph-
positive CML patients display a larger BCR-ABL1 fusion
transcript that results from a fusion between BCR exon 19
(originally named c3) and ABL exon 2. This is caused by
breakpoints in the -breakpoint cluster region (-bcr) be-
tween BCR exons 19 and 20 (van Dongen et al., 1999). This
e19a2(c3/a2)junctionyieldsatranscriptthatcontainsanad-
ditional BCR sequence of 540 bp and encodes for a chimeric
protein carrying 180 additional amino acids, as compared
with that found in typical CML (Pane et al., 1996).
In60to80%ofallpatientswithPh-positiveALL,the
breakpoint occurs in the first intron of the BCR gene, in a
region referred to as the minor breakpoint cluster region
(m-bcr), thereby producing the shorter isotype p190 BCR-
ABL1 from the e1a2 type mRNA (Deininger et al., 2000).
Although the e1a2 type of transcript has been mainly asso-
ciated with ALL, sporadic cases of CML expressing only
thistypeoftranscripthavealsobeenreported(Sellerietal.,
1990).
The majority of CML patients have transcripts with
theb3a2(55%)orb2a2(40%)junctions.In5%ofthecases,
both b3a2 and b2a2 transcripts can be formed as a result of
alternative splicing (Melo, 1996).
Thisstudywascarriedouttodeterminethefrequency
of expression of BCR-ABL1 fusion transcript variants in
Sudanese CML patients by using RT-PCR, and was partly
motivated by the introduction of imatinib mesylate, whose
administration is currently based on the molecular diagno-
sis of BCR-ABL1 fusion genes.
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Short CommunicationBlood samples from 46 patients with preliminary di-
agnosis of CML for the period 2004 to 2008, were obtained
for confirmation by molecular studies. Preliminary diagno-
sis was carried out according to clinical presentation and
morphological criteria of blood and bone marrow. Written
informedconsentwasobtainedfromallthepatientsorfam-
ily members.
Venous blood (5 mL) in EDTA tubes was collected
fromtheCMLpatients.Buffycoatwasisolatedandwashed
in red cells lysis buffer. Total RNA was extracted from
about 10
6 white cells by Trizol (Invitrogen). RNA integrity
wasdeterminedbygelelectrophoresispriortoreversetran-
scription.
For cDNA synthesis, the concentration of RNA was
first measured spectrophotometrically, and then the cDNA
was synthesized using M-MuLV Reverse Transcriptase
and other reaction components (Fermentas). 2 go fR N A
were reverse transcribed with 200 units of M-MuLV RT in
areactionmixconsistingof1xRTbuffer(50mMTris-HCl
, 50 mM KCl, 4 mM MgCl2, 10 mM DTT), 0.5 go f
oligo(dT)18, 20 mM dNTP and 20 units RNase inhibitor, in
afinalvolumeof20L.Reactionconditionswere70°Cfor
5min,37°Cfor5min,42°Cfor1hand70°Cfor10min.
BCR-ABL1 transcripts were detected by PCR, using
allele-specific primers for p210 and p190 primer se-
quences, as already described (van Dongen et al., 1999).
The (A2) primer ‘5 TTC AGC GGC CAG TAG CAT CTG
ACT T 3’ was also used for ABL1 as forward together with
a reverse primer. PCR was carried out in a total volume of
23 L of a reaction mixture containing 2.5 L of 10X PCR
buffer (10 mM Tris-HCl pH 8.3, 50 mM KCl), 2.5 Lo f
25 mM MgCl2,1L of 10 mM dNTPs, 2 Lo f1 0Mo f
forward and reverse primers, 14 Lo fH 2O and 1 Lo f
1U/L Taq DNA polymerase. A touchdown program was
employed, under the following conditions: an initial dena-
turationstepat95°Cfor3min.,thenfollowedby14cycles
of denaturing at 94 °C for 20 s, primer annealing at 64 °C
and a decrease 0.5 °C per cycle for 30 s, extension at 72 °C
for 45 s, then 35 cycle as following: denaturing at 94 °C for
20 s, primer annealing at 58 °C for 30 s, extension at 72 °C
for 45 s and a final extension step at 72 °C for 5 min. PCR
was done using separate reactions for each pair of primers.
The PCR products were visualized directly on ethidium
bromide-stained 2% agarose gel. ABL1 gene was used as
internal control. Bands of 417 bp, 342 bp, 957 bp and
226 bp were observed for b3a2, b2a2, e19a2 and normal
ABL1, respectively.
ThePCRproductsweresentforcommercialsequenc-
ing at Macrogen Company (South Korea).
The Chi square method was applied for comparing
obtained BCR-ABL1 variants of the CML patients by gen-
der.
Of the 46 patients studied, 43 were positive for one or
more of the BCR-ABL1 rearrangements. The b2a2 tran-
script was detected in 23 (53.5%) of the CML patients,
b3a2 in 18 (41.9%), both b2a2 and b3a2 in one (2.3%) pa-
tient, and b2a2, b3a2 with e19a2 also in one (2.3%) patient.
The e1a2 transcript was not detected. Of the 43 CML pa-
tients, 20 were males, 15 expressing b2a2, and 23 females,
13 of which expressing b3a2, and two females showed
co-expression. We found a correlation between the ob-
tained BCR-ABL1 variants and the sex type of the CML
patients (p = 0.017). Table 1 shows the BCR-ABL1 tran-
script types and the patients’ gender.
The distribution of transcript type in CML has been
studiedinEuropeanandsomeotherpopulations(Eisenberg
et al., 1988; Lee et al., 1989) with frequencies for b2a2 and
b3a2 transcripts being roughly of the order of 40% and
55%, and that for co-expression of b3a2 and b2a2 repre-
senting 5% of the cases. A study on an Ecuadorian popula-
tion,however,registeredverydifferentfrequencies:5%for
b3a2 and 95% for b2a2 (Paz-y-Mino et al., 2002). In the
present study, a frequency of 53.5% and 41.9% for b2a2
andb3a2,respectively,wasestablished,valueswhichareis
relatively closer to those from a Mexican population (Ara-
na-Trejo et al., 2002). This difference in frequencies may
be due to the genetic background of the populations.
Furthermore, it was found that CML patients at diag-
nosis also expressed either low e1a2 transcript frequency,
besides the usual BCR-ABL1 p210 (Saglio et al., 1996;
Van Rhee et al., 1996), or only 5% (Arana-Trejo et al.,
2002), or no co-expression whatsoever (Yaghmaie et al.,
2008).Inthisstudywedidnotdetectco-expressionofp210
and p190 in any of the Sudanese patients. This may be due
to technique sensitivity, although ethnic differences cannot
be disregarded.
We found a significant correlation between sex and
transcripttype,inwhichmalepatientsshowedahigherten-
dencyofexpressingb2a2andfemalesahighertendencyfor
b3a2(p=0.017).ThisisinagreementwithastudybyAdler
et al. (2009), which included 146 paediatric patients with
CML and reported the following proportions for the b2a2
transcript [34 males (51%) vs. 21 females (27%)], and in-
versely for the b3a2 [17 males (25%) vs. 36 females
(45%)]. In all these cases, the sex-dependent skewed distri-
bution in BCR-ABL1 transcript types deserves further in-
vestigation.
In this study, only two patients (4.6%) manifested
co-expression, one expressed b3a2/b2a2 and the other
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Table 1 - Incidence of BCR-ABL1 transcripts and gender.
BCR-ABL re-arrangement Case (%) Gender (male/female)
b2a2 23 (53.5%) 15/8*
b3a2 18 (41.9%) 5/13*
b2a2/b3a2 1 (2.3%) 0/1
b2a2/b3a2/e19a2 1 (2.3%) 0/1
*p = 0.017.b3a2/b2a2 with e19a2. Co-expression may arise either
from alternative splicing, or the existence of several leuke-
mia cell lines with different BCR-ABL1 transcript expres-
sion.
Co-expression of b2a2 and b3a2 transcripts has been
linked to two polymorphisms, T to C at exon 13 and A to G
at intron 13 (Meissner et al., 1998; Branford et al., 2002).
Six PCR products from four patients were sequenced to
confirm the products of four b2a2 and two b3a2 and one
was found to harbor T to C at exon 13 and expressed only
b2a2 transcript which might indicate that this exonic poly-
morphism is not obligatory for co-expression, as reported
by Mondal et al. (2006). Moreover, this polymorphism has
no implication on the primary structure of BCR and
BCR-ABL1 proteins. However, since the alteration is lo-
catedclosetothefusionregion,itmayhaveasignificantin-
fluence on the annealing of PCR primers, probes for real
time PCR, and antisense oligonucleotides. We intend to
study this polymorphism in a larger set of CML samples.
Finally, the difference in size of BCR-ABL1 tran-
scripts is not only a reflection of variation at the sites of
breakage/fusion, but is also a result of alternative splicing
between BCR and ABL and within BCR itself.
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